Lubrizol Sells Active Pharmaceutical Ingredient and Intermediate Compounds Business
This is Lubrizol's fifth and last planned divestiture since it announced its intent in July to market non-core businesses with combined revenues of $500 million. A&I has been part of Lubrizol's consumer specialties product line in the Specialty Chemicals segment. A&I management anticipates that 2006 sales revenues will be approximately $30 million U.S. Terms of the sale were not disclosed. A&I develops and produces active pharmaceutical ingredients and advanced intermediates that are marketed to proprietary and generic drug manufacturers worldwide.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.